 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...3435363738394041424344...235236» |
- albumin-bound paclitaxel / Generic mfg.
NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_68;
P3
First-line NALIRIFOX demonstrated clinically meaningful and statistically significant improvement in OS and PFS compared with Gem+NabP in patients with mPDAC. The NALIRIFOX safety profile was consistent with the profiles of the regimen components and generally manageable.
- 5-fluorouracil / Generic mfg.
Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy (CRT) or chemotherapy (CT) alone for non-resectable locally advanced pancreatic cancer (LAPC): Results of the CONKO-007 trial (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_66;
The NALIRIFOX safety profile was consistent with the profiles of the regimen components and generally manageable. Patients (pts) received induction chemotherapy (IC) for 3 m (3 cy gemcitabine (Gem, 1000mg/m
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Upfront surgery in cUICC-II/III upper rectal cancer followed by FOLFOX chemotherapy (CTx) (Hall A) - Sep 30, 2023 - Abstract #DGHO2023DGHO_54;
After standardized surgery, CTx with FOLFOX offers improved OS to patients with stage III upper rectal cancer. AdCTx was applicable with a good safety profile and a high compliance rate.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Journal: Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study. (Pubmed Central) - Sep 29, 2023
AdCTx was applicable with a good safety profile and a high compliance rate. Patients with a GI malignancy (n
- | 5-fluorouracil / Generic mfg.
Journal: Efficacy of press needle treatment in reducing chemotherapy-induced nausea, vomiting, and retching gastrointestinal cancer patients: A (Pubmed Central) - Sep 28, 2023
The control group received 5-hydroxytryptamine-3 (5-HT3) antagonists and dexamethasone 30 min before chemotherapy, followed by dexamethasone on days 2 and 3 after chemotherapy...Chinese Clinical Trial Registry (No. ChiCTR1900024554).
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial completion date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Sep 28, 2023
P3, N=5937, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
ChiCTR1900024554). Trial completion date: Jan 2024 --> Sep 2024
- || misetionamide (GP-2250) / Panavance Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine (clinicaltrials.gov) - Sep 28, 2023
P1, N=64, Recruiting, Sponsor: Geistlich Pharma AG
Trial completion date: Jan 2024 --> Sep 2024 Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
- || Trial completion date, Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=79, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Dec 2022 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Mar 2024 Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
- | Trial completion date, Trial primary completion date, Metastases: GABRINOX2: Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients (clinicaltrials.gov) - Sep 28, 2023
P2, N=162, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023 Trial completion date: Jan 2025 --> Nov 2027 | Trial primary completion date: Jul 2023 --> Mar 2027
- | Tecentriq (atezolizumab) / Roche
Enrollment open, Trial initiation date: Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov) - Sep 28, 2023
P2, N=240, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2025 --> Nov 2027 | Trial primary completion date: Jul 2023 --> Mar 2027 Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jun 2024
- zolbetuximab (IMAB362) / Astellas
Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2?, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma (Bilbao Auditorium - NCC) - Sep 27, 2023 - Abstract #ESMO2023ESMO_4229;
P3
Methods Pts were randomly assigned 1:1 to zolbetuximab IV 800 mg/m2 (cycle 1, day [D] 1) followed by 600 mg/m2 (every 3 weeks) + mFOLFOX6 IV (D1, 15, 29) for four 42-day cycles or to PBO + mFOLFOX6; pts without progressive disease (PD) continued with zolbetuximab or PBO, + folinic acid and 5-FU at investigator's discretion, until PD or discontinuation criteria were met...Most common TEAEs with zolbetuximab + mFOLFOX6 were nausea (zolbetuximab arm: 82.4% vs PBO arm: 61.5%), vomiting (67.4% vs 36.3%), and decreased appetite (48.7% vs 34.9%); incidences of serious TEAEs were similar between arms (47.0% vs 46.4%). Conclusions With longer follow-up, zolbetuximab + mFOLFOX6 continued to demonstrate statistically significant improvement in PFS and OS compared with PBO + mFOLFOX6, with no new safety signals
- nisevokitug (NIS793) / Novartis
TGF? blockade in pancreatic cancer enhances sensitivity to combination chemotherapy (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1127;
P1, P2, P3
This study provides scientific rationale for evaluation of NIS793 with either FOLFIRINOX or gemcitabine/n(ab)paclitaxel chemotherapy backbone in the clinical setting (NCT04390763, NCT04935359, NCT05546411, NCT05417386). We also support the concept of manipulating cancer cell plasticity to increase efficacy of combination therapy regimens.
- givastomig (TJ-CD4B) - I / Mab, ABL Bio
Givastomig, a novel Claudin18.2/4 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1121;
We also support the concept of manipulating cancer cell plasticity to increase efficacy of combination therapy regimens. In addition, givastomig-mediated T cell activation and tumor-killing was enhanced in combination with chemotherapies used in 1L or 2L treatment for gastric cancer, including 5-fluorouracil plus oxaliplatin (FOLFOX) and paclitaxel...2 expression (25
- Repeated dosing of anti-Claudin 18.2 CAR-T in metastatic gastrointestinal cancer (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_996;
P1b/2
Patients received a pre-conditioning regimen of fludarabine, cyclophosphamide, and 100mg/m2 nab-paclitaxel before CT041 CAR-T infusion...Results A 57-year-old man with metastatic gastric cancer to the liver (HER2 negative, PD-L1 CPS 10%) progressed after 5 cycles of FOLFOX+Nivolumab and 4 cycles of FOLFIRI/Ramucirumab...Again, he had G1 CRS with fever, which was resolved without tocilizumab...Conclusions Repeated dosing of anti-claudin 18. 2 CAR-T cells (CT041) was safe and deepened tumor response was observed after repeated dosing.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Dissecting pancreatic cancer tumor-immune microenvironment crosstalk using spatial transcriptomics (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_992;
P2
14 A randomized multi-institutional clinical trial of FOLFIRINOX +/- losartan +/- nivolumab (anti-PD1) for PDAC has been completed (NCT03563248)...15 A pilot trial demonstrated a 29% disease control rate with combined nivolumab + ipilimumab and radiation therapy...Conclusions Spatial transcriptomics and proteomics reveal insights into the spatial relationship between PDAC tumor cell EMT plasticity, CAFs, and immune infiltrates. This enables the discovery of novel immune response biomarkers and potential therapeutic avenues to target tumor and microenvironment interactions.
- IMM-101 / Immodulon
Collagen remodeling biomarkers in patients with locally advanced pancreatic cancer treated with stereotactic body radiotherapy plus intradermal heat-killed mycobacterium obuense (IMM-101) vaccination (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_413;
This enables the discovery of novel immune response biomarkers and potential therapeutic avenues to target tumor and microenvironment interactions. In the LAPC-2 trial, patients with non-progressive locally advanced pancreatic cancer (LAPC) after treatment with FOLFIRINOX, were included...Moreover, the treatment resulted in increased levels of the C4G/C4M ratio in patients with partial response suggesting that this biomarker ratio
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
P2 data, Review, Journal: A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. (Pubmed Central) - Sep 27, 2023
In an effort to reduce toxicities and optimize outcomes, this investigation explores the safety and feasibility of substituting liposomal irinotecan (nal-IRI) for nonliposomal irinotecan to improve tumor drug delivery and potentially reduce toxicity. This regimen, NALIRIFOX, has the potential to be both safer and more effective when administered in the preoperative setting.
- | Kuvan (sapropterin) / Merck (MSD), BioMarin, Daiichi Sankyo
Journal, Metabolomic study: Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior. (Pubmed Central) - Sep 26, 2023
Examination of metabolic disorders in treatment refractory depression identified an unexpectedly large proportion of patients with potentially treatable abnormalities. The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined.
- || albumin-bound paclitaxel / Generic mfg.
Clinical protocol, P2 data, Journal: Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial. (Pubmed Central) - Sep 26, 2023
P2
The etiology of these abnormalities and their potential roles in pathogenesis remain to be determined. This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.
- | irinotecan / Generic mfg.
New trial: XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) (clinicaltrials.gov) - Sep 26, 2023
P=N/A, N=98, Not yet recruiting, Sponsor: Guangzhou University of Traditional Chinese Medicine
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Enrollment open, Trial initiation date: TORCH-R: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer (clinicaltrials.gov) - Sep 26, 2023
P2, N=93, Recruiting, Sponsor: Fudan University
This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes. Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Aug 2022
- | Avastin (bevacizumab) / Roche
Biomarker, Journal, Metastases: Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer. (Pubmed Central) - Sep 25, 2023
This study sought a subset of CRC patients with a distinct clinical response to chemotherapy containing bevacizumab. Our results need to be validated in a large group of homogenous patient cohort and examined according to the different chemotherapy backbones to create personalized therapeutic opportunities in CRC.
- || ginisortamab (UCB6114) / UCB
Trial completion date, Trial primary completion date, Metastases: ONC001: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 25, 2023
P1/2, N=250, Recruiting, Sponsor: UCB Biopharma SRL
Our results need to be validated in a large group of homogenous patient cohort and examined according to the different chemotherapy backbones to create personalized therapeutic opportunities in CRC. Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Sep 2023 --> Feb 2024
- | irinotecan / Generic mfg., gemcitabine / Generic mfg.
Journal, Metastases: Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine. (Pubmed Central) - Sep 23, 2023
Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Sep 2023 --> Feb 2024 Gemcitabine showed better survival in patients with extremely low baseline CD8
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal, Metastases: Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. (Pubmed Central) - Sep 22, 2023
P2
A more complete assessment of MAPK pathway mutations warrants further investigation to the refine treatment strategy for patients with RAS wild-type mCRC. ClinicalTrials.gov Identifier: NCT02404935.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI?based treatment. (Pubmed Central) - Sep 22, 2023
Moreover, both dose reduction and RDI of irinotecan had no statistically significant difference in both PFS and OS. In the advanced colorectal cancer patients who received FOLFIRI based treatment as first-line regimen, chemotherapy dose delay and reduction dose of 5-Fu were associated with worse survival, especially among patients younger than 65 years.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (clinicaltrials.gov) - Sep 22, 2023
P3, N=1007, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
In the advanced colorectal cancer patients who received FOLFIRI based treatment as first-line regimen, chemotherapy dose delay and reduction dose of 5-Fu were associated with worse survival, especially among patients younger than 65 years. Trial primary completion date: Feb 2023 --> Feb 2024
- Protein translation inhibition enforces histone deacetylase inhibitor activity resulting in synergistic pancreatic cancer cell death (Level 2, Exhibit Hall D) - Sep 22, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_706;
- A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients (pts) with cachexia and elevated GDF-15 levels (Level 2, Exhibit Hall D) - Sep 22, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_705;
- ||| 5-fluorouracil / Generic mfg.
P3 data, Journal, Metastases: Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. (Pubmed Central) - Sep 21, 2023
P3
Although underpowered and incomplete, Neo-AEGIS provides the largest comprehensive randomised dataset for patients with adenocarcinoma of the oesophagus and oesophagogastric junction treated with perioperative chemotherapy (predominantly the modified MAGIC regimen), and CROSS trimodality therapy, and reports similar 3-year survival and no major differences in operative and health-related quality of life outcomes. We suggest that these data support continued clinical equipoise.
- | Trial completion date, Trial primary completion date: Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer (clinicaltrials.gov) - Sep 21, 2023
P2, N=38, Recruiting, Sponsor: Rutgers, The State University of New Jersey
We suggest that these data support continued clinical equipoise. Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
- | pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Trial completion date, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=126, Active, not recruiting, Sponsor: SWOG Cancer Research Network
Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024 Trial completion date: Jul 2023 --> Dec 2023
- | New trial, Metastases: GemSign-01: Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=100, Not yet recruiting, Sponsor: Institut Paoli-Calmettes
- |||||| Vyloy (zolbetuximab-clzb) / Astellas
New trial, Metastases: Early Access Program for Zolbetuximab (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=0, Available, Sponsor: Astellas Pharma Global Development, Inc.
- | New trial: A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=180, Enrolling by invitation, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- |||| quemliclustat (AB680) / Arcus Biosci, Gilead
New P2 trial, Combination therapy, Checkpoint inhibition, Checkpoint block, Metastases: AIRPanc: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Sep 21, 2023
P2, N=60, Recruiting, Sponsor: Gulam Manji
- |||| temozolomide/perillyl alcohol conjugate (NEU001) / NeOnc Technologies, NeuCen BioMed
New P1/2 trial, IO biomarker: Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=134, Not yet recruiting, Sponsor: Neonc Technologies, Inc.
- ||| onvansertib (PCM-075) / Cardiff Oncology
Enrollment closed, Enrollment change, Trial primary completion date: ONSEMBLE: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation (clinicaltrials.gov) - Sep 21, 2023
P2, N=23, Active, not recruiting, Sponsor: Cardiff Oncology
Trial completion date: Jul 2023 --> Dec 2023 Recruiting --> Active, not recruiting | N=150 --> 23 | Trial primary completion date: Nov 2024 --> Nov 2025
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Serum basic fibroblast growth factor and interleukin-1? predict the effect of first-line chemotherapy in patients with advanced gastric cancer. (Pubmed Central) - Sep 21, 2023
Recruiting --> Active, not recruiting | N=150 --> 23 | Trial primary completion date: Nov 2024 --> Nov 2025 The FLOT regimen was effective in reducing the serum CEA, CA199, and TPS levels as well as in improving the 1-year survival rate of patients with good tolerability, making it worthy of clinical promotion and application.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer. (Pubmed Central) - Sep 19, 2023
The PC modeling approach offers flexible characterization of associations between longitudinal covariates, such as serially assessed tumor burden, and survival time. It can be applied to a variety of data of this nature and used as clinical trials are ongoing to incorporate new disease assessment information as it is accumulated, as indicated by an example from colorectal cancer.
- | Journal, Surgery, Metastases: Comparison of neoadjuvant versus upfront surgery for treatment of locally advanced gastric cancer. (Pubmed Central) - Sep 19, 2023
It can be applied to a variety of data of this nature and used as clinical trials are ongoing to incorporate new disease assessment information as it is accumulated, as indicated by an example from colorectal cancer. Although we found no significant difference between the patients undergoing standard gastrectomy and those undergoing NACT before gastrectomy, we believe that NACT may contribute to the favorable prognosis of patients with locally advanced disease with improved OS and DFS and this should be examined in future studies.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Real-world evidence, Real-world, Metastases: Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study. (Pubmed Central) - Sep 19, 2023
Although we found no significant difference between the patients undergoing standard gastrectomy and those undergoing NACT before gastrectomy, we believe that NACT may contribute to the favorable prognosis of patients with locally advanced disease with improved OS and DFS and this should be examined in future studies. Our real-world data analysis suggests that the addition of anti-VEGF to FOLFOX offers limited and short-lived benefits in the context of mCRC and may provide differential survival benefit based on tumor sidedness.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Patient reported outcomes: Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea. (Pubmed Central) - Sep 18, 2023
Our real-world data analysis suggests that the addition of anti-VEGF to FOLFOX offers limited and short-lived benefits in the context of mCRC and may provide differential survival benefit based on tumor sidedness. No abstract available
- | Journal, HEOR, Real-world evidence, Real-world: Real-world treatment patterns and survival outcomes for treated biliary tract cancer patients using administrative databases in Ontario. (Pubmed Central) - Sep 18, 2023
Survival in treated patients is higher than that in untreated patients. Our findings highlight the unmet need for effective systemic therapies for BTC.
- | zolbetuximab (IMAB362) / Astellas
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma. (Pubmed Central) - Sep 18, 2023
At a willingness-to-pay threshold of $38,201/QALY, ZOL-FO had a 0% probability of cost-effectiveness compared with PLB-FO. From the perspective of the Chinese healthcare system, ZOL-FO is unlikely to be cost-effective as the first-line treatment option for CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma.
- | 5-fluorouracil / Generic mfg.
Journal: Babao Dan alleviates gut immune and microbiota disorders while impacting the TLR4/MyD88/NF-?B pathway to attenuate 5-Fluorouracil-induced intestinal injury. (Pubmed Central) - Sep 18, 2023
Furthermore, at the genus level on the fifth day, BBD upregulated the abundance of unidentified_Corynebacteriaceae, Aerococcus, Blautia, Jeotgalicoccus, Odoribacter, Roseburia, Rikenella, Intestinimonas, unidentified_Lachnospiraceae, Enterorhabdus, Ruminiclostridium, and downregulated the abundance of Bacteroides, Parabacteroides, Parasutterella, Erysipelatoclostridium, which were highly correlated with intestinal injury or the TLR4/MyD88/NF-?B pathway. In conclusion, we established a network involving 5-FU, BBD, the immune response, gut microbiota, and key pathways to explain the pharmacology of oral BBD in preventing 5-FU-induced intestinal injury.
- | Tevimbra (tislelizumab-jsgr) / BeiGene
Phase classification: SYLT-023: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab (clinicaltrials.gov) - Sep 18, 2023
P1/2, N=20, Recruiting, Sponsor: Fujian Cancer Hospital
In conclusion, we established a network involving 5-FU, BBD, the immune response, gut microbiota, and key pathways to explain the pharmacology of oral BBD in preventing 5-FU-induced intestinal injury. Phase classification: P1 --> P1/2
- || BOLD-100 / Bold Therap
Enrollment closed, Combination therapy, Metastases: BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrials.gov) - Sep 18, 2023
P1b/2a, N=117, Active, not recruiting, Sponsor: Bold Therapeutics, Inc.
Phase classification: P1 --> P1/2 Recruiting --> Active, not recruiting
- irinotecan / Generic mfg.
An SN38 dendrimer nanoparticle, DEP irinotecan (SN38-SPL9111), demonstrates efficacy in mouse models of gastrointestinal cancer and augments anti-tumor effects of immune checkpoint blockade and PARP inhibition. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_655;
- Discovery of new drug combinations for metastatic colorectal cancer. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_535;